Together with scientists from Erasmus MC, Radboudumc has signed a license agreement with Sebia, world leader in multiple myeloma diagnostics. This partnership enables the development of an ultra-sensitive blood assay that can detect minimal residual disease (MRD) in myeloma patients to guide optimal personalized treatment. Currently, MRD status is assessed on bone marrow aspirates. However, bone marrow sampling is invasive and introduces the risk of non-representative sampling due to heterogenous disease spreading. The new personalized targeted mass spectrometry technology developed by Erasmus MC and Radboudumc allows MRD monitoring directly in serum of myeloma patients.
“Through personalized diagnostics on one drop of blood, we can create a patient-friendly alternative to monitor MRD in myeloma patients,” says principle investigator Hans Jacobs, Theme Cancer development and immune defense. “This allows dynamic monitoring of patients with deep responses, which is crucial for early detection of disease relapse. This assay will greatly support the path towards precision medicine in these patients.”
"In this approach we combine technology innovation with clinical impact by developing and applying truly personalized diagnostics for Multiple Myeloma care, a beautiful showcase of translational biomarker work by collaboration", says Alain van Gool, Theme Metabolic disorders.